Copy Link Print Information

Inebilizumab

(Synonyms: MEDI-551)
1 Cited Publications
Revisión del cliente

Based on 1 publication(s) in Google Scholar

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 99.23%
  • No. CAS: 1299440-37-1
  • Peso molecular:150 kDa
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Inebilizumab
  • Experimental Validation Results for Inebilizumab
  • Experimental Validation Results for Inebilizumab
  • Experimental Validation Results for Inebilizumab
  • Inebilizumab Chemical Structure
    Inebilizumab Chemical Structure
No. CAS: 1299440-37-1
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Inebilizumab:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Inebilizumab

More
Customer Validation & Images
Flow Cytometry
  • Flow Cytometry

Keywords

MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Inebilizumab has a significant ADCC effect on CHOK1-hCD19 cells in a dose-dependent manner.The EC50 for this effect is 61.53 ng/mL.

  • 1/16

    Loaded Inebilizumab on AHC2 biosensor, can bind CD19 Protein, Human (HEK293, His, HY-P74330) with an affinity constant of 1.240E-09 M as determined in BLI assay.

  • 1/16

    Inebilizumab purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Oct;14(10):4560-4576. [Abstract]

    Customer Validation
     Human PBMCs were treated with 100 nmol/L TP, 100 nmol/L TP-PEG, 10 nmol/L ADC-TP (IgG), 10 nmol/L Den, 10 nmol/L Inebilizumab (Ine), 10 nmol/L ADC-TP (Den), and 10 nmol/L ADC-TP (Ine) for 48 h, the frequencies of CD19+ B cells were analyzed by flow cytometry.

  • Inebilizumab Chemical Structure
    1/16
  • Inebilizumab
  • Inebilizumab has a significant ADCC effect on CHOK1-hCD19 cells in a dose-dependent manner.The EC50 for this effect is 61.53 ng/mL.
  • Loaded Inebilizumab on AHC2 biosensor, can bind CD19 Protein, Human (HEK293, His, HY-P74330) with an affinity constant of 1.240E-09 M as determined in BLI assay.